Case Report: Two Case Reports of Pulmonary Hypertension after mRNA COVID-19 Vaccination
Open Access
Abstract
Background: We herein report two cases of sudden onset symptomatic pulmonary hypertension after coronavirus disease 2019 (COVID-19) vaccination. Case Summary: Pulmonary hypertension in previously healthy adult males occurred within three weeks of receiving the second dose of the Pfizer (BNT162b2) mRNA COVID-19 vaccine from different lots. Both patients experienced a sudden onset of severe fatigue and dyspnea on exertion with negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) testing. The diagnosis was made by serial transthoracic echocardiography in the first case and by both transthoracic echocardiography and right heart catheterization in the second. Both cases resulted in functional limitations and likely permanent organ damage. No evidence of pulmonary emboli was detected in either case. Discussion: Pulmonary hypertension is a serious disease characterized by damage to lung vasculature and restricted blood flow through narrowed arteries from the right to left heart. The onset of symptoms is typically insidious, progressive and incurable, leading to right heart failure and premature death. The World Health Organization (WHO) classifies pulmonary hypertension into five categories and recently re-defined it as a resting mean pulmonary artery pressure greater than 20 mmHg. Sudden onset pulmonary hypertension would only be expected in the settings of surgical pneumonectomy or massive pulmonary emboli with compromise of at least 50% of the lung vasculature. We present here two novel cases of sudden onset pulmonary hypertension without evidence of pulmonary emboli, both of which occurred after receiving a COVID-19 mRNA vaccine.Keywords
All Related Versions
Funding Information
- National Institutes of Health (R03AG071596, R21AG073919)
This publication has 25 references indexed in Scilit:
- Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial HypertensionChest, 2018
- Imaging of acute pulmonary embolism: an updateCardiovascular Diagnosis and Therapy, 2018
- Acute and Chronic Right Ventricular Failure2017
- Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertensionScientific Reports, 2017
- Assessment of pulmonary artery pressure by echocardiography—A comprehensive reviewIJC Heart & Vasculature, 2016
- When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be foundBMJ, 2013
- Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agentDrug Design, Development and Therapy, 2009
- Study on the late effect of pneumonectomy on right heart pressures using Doppler echocardiographyEuropean Journal of Cardio-Thoracic Surgery, 2004
- Continuous wave doppler determination of right ventricular pressure: A simultaneous Doppler-catheterization study in 127 patientsJACC, 1985
- The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary diseaseThe American Journal of Cardiology, 1971